Search
Nashville, TN Paid Clinical Trials
A listing of 1255 clinical trials in Nashville, TN actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
877 - 888 of 1255
There are currently 1255 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Reciprocal Imitation Training and Musical Rhythm Sensitivity in Autistic Toddlers
Recruiting
The primary goal of this study is to examine rhythm sensitivity as a predictor of response to naturalistic developmental behavioral intervention (NDBIs) in autistic toddlers. Toddlers receive either Reciprocal Imitation Training (RIT), an evidence-based NDBI that supports children's imitation and social communication skills, or a music-enhanced version of RIT. Throughout their participation in the intervention, toddlers will complete study procedures of viewing naturalistic videos of infant-dire... Read More
Gender:
ALL
Ages:
Between 18 months and 36 months
Trial Updated:
04/22/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Autism, Autism Spectrum Disorder
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Recruiting
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: GSK Investigational Site, Nashville, Tennessee
Conditions: Hypereosinophilic Syndrome
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Recruiting
This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations,uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Non-Small Cell Lung Cancer
Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)
Recruiting
Benign central airway stenosis (BCAS) is an important cause of both pulmonary morbidity and mortality. Notable causes include post-intubation stenosis, collagen vascular diseases, airway trauma, infectious and idiopathic subglottic stenosis (iSGS). Surgery is the preferred definite option; however, the first therapeutic attempt is usually endoscopic to temporarily restore airway patency and symptomatic improvement.
Several endoscopic modalities exist for treatment. Most commonly, thermal or las... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Pulmonary Disease
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Vanderbilt, Nashville, Tennessee
Conditions: Peripartum Cardiomyopathy, Postpartum
TVMR With the Innovalve System Trial - Early Feasibility Study
Recruiting
Study to evaluate the safety and performance of the Innovalve mitral valve replacement system
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Mitral Valve Regurgitation (Degenerative or Functional)
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
Recruiting
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Principal Investigator, Nashville, Tennessee
Conditions: Persistent Corneal Epithelial Defect
Combined Electric and Acoustic Hearing (EAS) in Children and Adults
Recruiting
Cochlear implants are surgically implanted devices which restore the ability to hear to the hearing impaired. Improvements in surgery and electrodes have results in an increased number of adults and children who have residual hearing and can benefit from electric and acoustic hearing in the same ear. This is called Electric Acoustic Stimulation (EAS). Many studies have shown that adult EAS users show significant benefits for speech understanding in noise and spatial hearing tasks as compared to... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
04/18/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Cochlear Implant, Hearing Loss
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Recruiting
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
Recruiting
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Aortic Aneurysm, Abdominal
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Recruiting
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Research Site, Nashville, Tennessee
Conditions: Solid Tumors
Genetics of Appendix Cancer Study
Recruiting
The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Appendix Cancer, Appendiceal Cancer, Appendiceal Neoplasms, Appendiceal Mucinous Neoplasm, Appendiceal Adenocarcinoma, Appendiceal Carcinoid Tumor, Appendiceal Neoplasm Malignant Secondary, Appendix Adenocarcinoma, Appendix Mucinous Neoplasm, Appendix Tumor, Appendix Cancer Metastatic, Appendix NET, Low-Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Adenocarcinoma
877 - 888 of 1255
